Trial · NCT02325362
Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
NCT02325362, Phase 2, Phase 3, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation. Trials, record NCT02325362. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02325362
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
- NCT number
- NCT02325362
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 16 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Cystic Fibrosis
- Interventions
- Miglustat ; placebo, Placebo ; Miglustat
- First posted
- 2014-12-25
- Last updated
- 2025-11-20
- Other registries' IDs
- eudract:2013-000497-29
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean TCS in mV | day 1 | TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient |
| Primary | Mean TCS in mV | Day 14 | TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient |
| Secondary | TCS difference in mV | day 1 | TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient. |
| Secondary | TCS difference in mV | Day 14 | TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient. |
| Secondary | Percentage of patients with a TCS response to treatment ≤ - 5 mV | day 1 | The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS response to treatment ≤ - 5 mV | day 14 | The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV | day 1 | The percentage of patients with a TCS response at end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV | day 14 | The percentage of patients with a TCS response at end-of-treatment ≤ -5mV |
| Secondary | Change of basal NPD in mV | day 1 | Basal NPD at end-of-treatment minus basal NPD at baseline |
| Secondary | Change of basal NPD in mV | day 14 | Basal NPD at end-of-treatment minus basal NPD at baseline |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02325362
GET https://conductscience.org/api/trials/v1/NCT02325362/registered?page=2